MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with Wisconsin-based SHINE Technologies, LLC (SHINE) for highly pure no-carrier-added (n.c.a.) lutetium-177 (177Lu), a therapeutic isotope used in Telixâs portfolio of molecularly targeted radiation (MTR) investigational products.
As Telix advances its late-stage clinical trials using the medical radiois...
>>> Read more: Telix and SHINE partner for Lutetium-177 Supply
As Telix advances its late-stage clinical trials using the medical radiois...
>>> Read more: Telix and SHINE partner for Lutetium-177 Supply